Skip to main content
. Author manuscript; available in PMC: 2024 Mar 1.
Published in final edited form as: Lancet Diabetes Endocrinol. 2023 Feb 1;11(3):169–181. doi: 10.1016/S2213-8587(22)00387-4

Figure 1: Participant recruitment and disposition.

Figure 1:

TG1 population.

Among those discontinuing treatment before week 26, on-treatment HbA1c was available for 1 participant.

Reasons for discontinuation of empagliflozin treatment described as ‘other reasons’ included:

1. Exclusionary lab was received more than 2 weeks after randomisation, participant was discontinued per sponsor.

2. Principal investigator decision to discontinue due to non-compliance.

3. Participant has decided to stop taking study medication and, following the study protocol, participant was willing to attend visit 8 only.

4. Despite many attempts to contact participant, person lost to follow-up.

HbA1c, glycated haemoglobin; mITT, modified intention-to-treat; TG, treatment groupings (see Treatment group definitions in this Supplementary Appendix for detailed explanation).